

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/144177/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Quaife, Samantha L., Waller, JO, Dickson, Jennifer L., Brain, Kate E. , Kurtidu, Clara, McCabe, John, Hackshaw, Allan, Duffy, Stephen W. and Janes, Samuel M. 2021. Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study. *Journal of Thoracic Oncology* 16 (12) , pp. 2016-2028. 10.1016/j.jtho.2021.07.025

Publishers page: <http://dx.doi.org/10.1016/j.jtho.2021.07.025>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



**Title:** Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study

**Authors:** Samantha L Quaife<sup>1</sup> PhD, Jo Waller<sup>2</sup> PhD, Jennifer L Dickson<sup>3</sup> MBBS, Kate E Brain<sup>4</sup> PhD, Clara Kurtidu<sup>5</sup> MSc, John McCabe<sup>3</sup> BSc, Allan Hackshaw<sup>6</sup> MSc, Stephen W Duffy<sup>1</sup> PhD, PhD, Samuel M Janes<sup>3</sup> PhD

**Corresponding author:** Dr Samantha L Quaife, s.quaife@qmul.ac.uk, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ

**Affiliations:** <sup>1</sup>Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; <sup>2</sup>School of Cancer and Pharmaceutical Sciences, King's College London, UK; <sup>3</sup>Lungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, UK; <sup>4</sup>Division of Population Medicine, Cardiff University, UK; <sup>5</sup>Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK; <sup>6</sup>Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, UK.

**Funding:** This study was funded by a Cancer Research UK (CRUK) Population Research Fellowship (C50664/A24460) awarded to SLQ. SLQ is also supported by Barts Charity (MRC&U0036). The SUMMIT Study, within which the present study's cohort is embedded, is funded by GRAIL. SMJ was a Wellcome Trust Senior Fellow in Clinical Science (WT107963AIA). SMJ is supported by CRUK, the Rosetrees Trust, the Roy Castle Lung Cancer foundation, the Stoneygate Trust, the Garfield Weston Trust and UCLH Charitable Foundation. This work was partly undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre's funding scheme. JW is supported by a CRUK career development fellowship (C7492/A17219). The funding agreements ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

**Conflict of interest:** SLQ, JW, KEB, CK and SWD declare no support from financial organisations that might have an interest in the submitted work in the previous three years. SMJ, JLD, JM and AH are investigators for an academic study (SUMMIT) within which the present study cohort is embedded. SUMMIT is sponsored and conducted by UCL and funded by GRAIL, Inc, through a research grant awarded to SMJ as Principal Investigator. SLQ collaborates on the SUMMIT Study. SMJ has been paid by Astra Zeneca, BARD1 Bioscience, Optellum, Jansen, Takeda and Achilles Therapeutics for being an Advisory Board Expert and travel to one US conference. SMJ receives grant funding from Owlstone for a separate research study. AH has received one honorarium for an advisory board meeting for GRAIL, Inc; and a consulting fee from Evidera Inc (for a GRAIL-initiated project); and previously owned shares in Illumina. All authors perceive that these disclosures pose no academic conflict for this study. All authors declare no other relationships or activities that could appear to have influenced the submitted work.

**Manuscript word count:** 3489 words

**Abstract word count:** 244

## **ABSTRACT**

**Introduction:** Low uptake of low-dose computed tomography (LDCT) lung cancer screening by high-risk groups compromises its effectiveness and equity as a population-level early detection strategy. Numerous psychological factors are implicated qualitatively or retrospectively, but prospective data are needed to validate their associations with uptake behaviour and specify psychological targets for intervention.

**Methods:** A prospective, longitudinal cohort study examining psychological correlates of lung cancer screening uptake. Ever smokers (aged 55-77) were invited to a Lung Health Check at which LDCT screening was offered through the SUMMIT Study; a multi-centre screening implementation trial. One week after their screening invitation, 44,000 invitees were sent the Self-Regulatory Questionnaire for Lung Cancer Screening. Regression analyses examined the constructs' associations with uptake (telephoning for an appointment) and sociodemographic characteristics.

**Results:** Higher odds of uptake were associated with both positive and negative perceptions. Positive perceptions included lung cancer controllability, benefits of early diagnosis, improved survival when lung cancer is detected early, willingness to be treated, and believing smoking cessation is effective in reducing risk. Negative perceptions included a higher lung cancer risk perception, negative beliefs about the consequences of lung cancer, perceiving lung cancer as stigmatised, and a negative emotional response. While current smokers held the highest risk perceptions, they also reported negative perceptions that could undermine how they behave in response to their risk.

**Conclusions:** Interventions to improve uptake should focus on changing perceptions that affect how an individual reacts when they believe their risk of lung cancer is high.

**KEY WORDS:** Lung cancer screening, Uptake, Inequalities, Intervention, Behavioral Sciences

## INTRODUCTION

Lung cancer causes almost one in five cancer deaths internationally<sup>1</sup> and contributes significantly to socioeconomic inequalities in premature mortality<sup>2</sup>. While tobacco control strategies remain the cornerstone of lung cancer control, achieving earlier diagnosis would markedly improve survival. Just 27% of patients are diagnosed with early-stage disease<sup>3</sup> for which one-year survival is 88%, compared with 19% for advanced disease<sup>4</sup>. Screening asymptomatic adults at high risk of lung cancer (due primarily to age and smoking history) using low-dose computed tomography (LDCT) detects early-stage disease, and significantly reduces lung cancer mortality<sup>5,6</sup>. It is implemented in the United States (US), Canada, Korea, regions of China, and Croatia, and is actively being considered in the UK and elsewhere.

The effectiveness and equity of LDCT screening implementation depend on a high-risk participant profile, which enriches cases and improves the risk-benefit ratio. Within the US National Lung Screening Trial (NLST), 88% of screen-prevented deaths were for those classified within the three highest-risk quintiles, for whom the false positive rate and number needed to screen were reduced<sup>7</sup>. However, participation has been low, particularly among high-risk groups. Tobacco smoking is the biggest risk factor and most prevalent within socioeconomically deprived communities<sup>8</sup>, yet fewer current smokers and lower socioeconomic groups participated across UK<sup>9</sup>, European<sup>10</sup> and US trials<sup>11</sup>. The same inequalities are observed in the US service context, where 2% of eligible smokers have been screened since its recommendation in 2013<sup>12</sup>.

It is critical to understand why high-risk groups are less likely to participate in LDCT screening to provide a scientific evidence base for intervention. The Common-Sense Model of Self-Regulation of Health and Illness (known as the Self-Regulation Model; SRM)<sup>13</sup> is a useful framework for conceptualising psychological determinants. According to the SRM, an individual's cognitive and affective perceptions of a health threat and the perceived efficacy of behaviours available to control both the threat and their emotional reaction to it, guide their coping response. When the protection behaviour (e.g., screening) is incongruent with an individual's understanding of the threat (e.g., lung cancer is invariably fatal), an individual may focus on reducing their emotional reaction instead of the threat itself. Indeed, qualitative and cross-sectional studies implicate negative cognitive and affective perceptions in low uptake of LDCT screening, including fatalism about risk and survival, low perceived efficacy of treatment, and fear of diagnosis<sup>14,15</sup>. This is on the basis that they are more frequently reported by high-risk groups<sup>14</sup>, retrospectively reported by those declining trial participation<sup>16–18</sup>, associated with lower screening intentions<sup>19</sup>, and observed during interviews with high-risk individuals deliberating about a hypothetical screening offer<sup>15</sup>.

Crucially, these perceptions may provide psychological targets for interventions to improve participation by high-risk groups. However, while studies corroborate similar psychological targets, these are numerous and diverse, and the strength of evidence for their effect on screening behaviour is limited by their small-scale, hypothetical, cross-sectional or retrospective designs. The potential psychological targets should be validated prospectively against behaviour in line with the experimental medicine approach to health behaviour change<sup>20</sup>. Using the SRM as a conceptual framework, we tested for the first time, whether (and which) of these psychological factors are associated with screening uptake behaviour prospectively using a longitudinal cohort design embedded within the SUMMIT Study<sup>21</sup>; a multi-centre LDCT screening implementation trial.

## **MATERIALS AND METHODS**

### **Study design**

A prospective, longitudinal cohort study design examined psychological correlates of LDCT lung cancer screening uptake behaviour across three annual screening rounds. This 'screening uptake and behaviour (SUB) cohort' is embedded within the SUMMIT Study<sup>21</sup>, which aims to assess implementation of LDCT lung cancer screening in a high-risk population and to validate a multi-cancer early detection blood test. This paper reports baseline findings from the SUB cohort.

### **Eligibility criteria**

To be eligible for the SUB cohort, individuals had to be eligible for invitation to a Lung Health Check (LHC) which was determined using data from individual primary care records. The inclusion criteria were: i) aged 55-77, and ii) primary care record of smoking tobacco (ever  $\leq 20$  years). Individuals were excluded if they had declined research, were receiving palliative care or active cancer treatment, had metastatic cancer, dementia, or were under the gold standards framework (life expectancy  $< 12$  months). Those who responded to the Lung Health Check invitation were asked a series of questions over the telephone and in-person at the Lung Health Check appointment, which collected more detailed information (than that in primary care) for determining their eligibility for LDCT lung cancer screening and therefore the SUMMIT Study.

### **Procedure**

Standardised electronic audit searches selected individuals for invitation to a LHC from primary care records. They were mailed the questionnaire and one reminder letter, within the sequence of LHC invitation letters (see Figure 1 for details). The invitation asked individuals to telephone a freephone number if they were interested in an LHC appointment at which LDCT screening may be offered. A prize draw was used to increase questionnaire response rates.

### **Ethics**

An NHS Research Ethics Committee (reference:17/LO/2004) and the UK Health Research Authority's Confidentiality Advisory Group (reference:18CAG0054) granted approval.

### **Measures**

#### ***Screening uptake***

The primary outcome was uptake of the LHC invitation, defined as telephoning to book an LHC appointment in response to the invitation letter (vs. not telephoning). This is the first active step in participating and we were interested in whether individuals would consider the offer; recognising some may choose not to participate. Data on LHC attendance (among those eligible following the phone screener) and uptake of LDCT screening (among those eligible at their LHC appointment) were descriptive secondary outcomes.

#### ***Psychological constructs***

The psychometrically validated Self-Regulatory Questionnaire for Lung Cancer Screening (SRQ-LCS, 25) was used to measure psychological constructs hypothesised to be associated

with uptake. The measure was developed using the SRM framework <sup>13</sup> to synthesise and operationalise psychological factors previously implicated in LDCT screening uptake.

The SRQ-LCS measures eleven psychological constructs, defined in Text Box 1 (items published <sup>22</sup>). They include seven three-item sub-scales (consequences, personal control, treatment control, illness control, emotional representation, early diagnosis behavioural response, risk perception) and four single items (response efficacy of smoking cessation, perceived stigma, treatment intention, survival from lung cancer). For the sub-scales, item responses (e.g., 1=strongly disagree, 2=disagree, 3=neither agree/disagree, 4=agree, 5=strongly agree) were summed to create a score (range 3-15), using reverse coding where relevant. Higher scores meant more positive perceptions (of consequences, emotional representation, early diagnosis behavioural response) or higher levels of the construct (perceived personal control, treatment control, coherence, and perceived risk). For the single item measures, responses were dichotomised.

**Text box 1** Definitions of SRQ-LCS psychological constructs (for a list of constructs' items see <sup>22</sup>)

<b>Construct name</b>	<b>Definition</b>
Consequences	Perceived severity of the consequences of lung cancer for the affected person and others close to them.
Personal control	Perceived ability to personally change the course of a lung cancer diagnosis, by making it better or worse.
Treatment control	Perceived effectiveness of treatment in curing or controlling lung cancer.
Illness coherence	Perceived personal knowledge and understanding of lung cancer.
Emotional representation/ response	Extent to which thinking about lung cancer makes the individual feel worried, anxious, or afraid.
Early diagnosis behavioural response	Perceived benefit of early diagnosis and willingness to be tested for lung cancer
Risk perception	Perceived personal risk of, and worry about, getting lung cancer.
Response efficacy of smoking cessation	Perceived efficacy of smoking cessation in reducing risk of lung cancer.
Perceived stigma	Perceived blame directed towards those with lung cancer by other people.
Treatment intention	Willingness to have surgery for a screen-detected early-stage lung cancer.
Survival from lung cancer	Perceived chances of surviving early-stage lung cancer.

### ***Demographic and smoking data***

Demographic information was collected from primary care, including age at data extraction, gender, ethnicity, and area-level deprivation (Indices of Multiple Deprivation (IMD) 2015 rank converted from residential postcode and recoded into national quintiles). Individuals' last recorded smoking status by primary care was also collected. The questionnaire collected self-reported smoking status, smoking history, tobacco consumption and tobacco dependence. Plausible thresholds for analysis of tobacco consumption were set (1-80 cigarettes daily) in line with previous research<sup>23</sup>. Self-reported smoking data were used in analyses.

### ***Primary statistical analyses***

Chi-square and multiple logistic regression analyses tested for associations between each of the psychological constructs and uptake of screening (telephone response vs. none).

### ***Secondary statistical analyses***

Descriptive analyses examined sample characteristics, response rates, and the relationship between screening uptake intentions and behaviour. Descriptive and multiple linear regression analyses were used to determine the distribution of psychological constructs overall, and their sociodemographic and smoking-related correlates. An alpha of 0.01 was used to adjust for multiple testing.

### ***Statistical power***

A sample of 1484 participants at the final SUB data collection wave (two years' follow-up) provides 80% statistical power to detect a small effect (OR=1.2 per SD of a continuous independent variable) of the independent variable on screening uptake, with a 5% significance level and two-sided testing<sup>24</sup>. To achieve this, 44,000 individuals were invited, assuming the following: i) 50% attrition (based on cohort retention rates for older adults within the lowest wealth quintile<sup>25</sup> and current smokers<sup>26</sup>), ii) 35% screening uptake rate based on the UK lung screening (UKLS) trial<sup>9</sup>, iii) 50% questionnaire response rate from attenders and 25% from non-attenders based on a UKLS non-participant study<sup>16</sup>, and iv) halving the final sample receiving annual screening due to (1:1) randomisation within the SUMMIT Study. With our more stringent significance criterion of 0.01, we would need 2,210 participants.

## **RESULTS**

### ***Response rate***

Between April and September 2019, the first 44,000 individuals (from 103 primary care practices) invited to an LHC as part of the SUMMIT Study were invited to complete the questionnaire and consent to ongoing follow-up as part of the SUB cohort (Figure 1). Of those invited, 7966 (18.1%) returned the questionnaire, 7730 of which were linked to screening uptake data. Most respondents (n=6921, 89.5%) returned the questionnaire within four weeks, with others taking up to two months (n=394, 5.1%), over two months (n=129, 1.7%) or their time to respond was unknown (n=286, 3.7%).

- Figure 1-

### ***Sample characteristics***

Compared with the overall invited group (Table 1), a lower proportion of questionnaire respondents were male (55.0% vs. 58.0%), of a black, Asian or minority ethnic background (18.9% vs. 26.5%), lived in the lowest deprivation quintile (27.8% vs. 33.8%) and reported being current smokers (40.0% vs. 48.9%). There were discrepancies between primary care recorded and self-reported smoking status. For example, 30.1% of respondents self-reported being current daily smokers compared with 40.0% as last recorded by primary care. While all individuals had been recorded by primary care as smoking historically (see Methods), a small proportion were recorded as never having smoked (3.5% self-reported). Respondents starting smoking at a mean age of 18.1 years (SD:5.9) and an average of 15.9 (SD:9.9) cigarettes daily. Amongst current smokers, tobacco dependence was high, with 60.3% smoking within 30 minutes of waking.

- Table 1-

### ***Behavioural intentions and screening uptake behaviour***

While 76.8% (5937/7730) intended to telephone to book an LHC (n=3651) or had already done so when completing the questionnaire (n=2286), two thirds (n=5257; 68.0%) actually telephoned to book an LHC. Most (n=2616/2854; 91.6%) underwent LDCT screening if eligible (Supplementary Table 1). The proportion carrying out each uptake behaviour (phone response, attending LHC, undergoing LDCT) varied by intentions as expected (Figure 2): positive intentions more frequently translated to the respective behaviour than negative. Unexpectedly, however, the majority (351/367, 95.6%) of eligible phone responders who had reported being 'very unlikely' to attend an LHC appointment actually attended. The weakest association between positive intentions and behaviour was for phone response, with 69.5% (2537/3651) of those intending to phone doing so.

- Figure 2 -

### ***Psychological correlates of screening uptake***

All the SRQ-LCS constructs were statistically significantly associated with uptake in adjusted analyses, except illness coherence and treatment control. Figure 3 presents the adjusted odds ratios indicating (for their interpretation) those relating to unit increases in sub-scale scores and those relating to changes in binary responses.

- Figure 3 -

The odds of uptake were statistically significantly higher for each unit increase in score (range 3-15) for three sub-scales. The strongest positive association was for those who perceived early diagnosis to be more beneficial as a behavioural response (aOR:1.37;1.33,1.41). Those who perceived greater personal control (aOR:1.09; 95% CI:1.05,1.11) or believed their personal risk of lung cancer was high (aOR:1.08;1.05,1.10) were also more likely to respond. However, higher scores on both the consequences (aOR:0.88;0.85-0.91) and emotional representation sub-scales (aOR:0.95;0.93-0.97; indicating more positive perceptions and representations) decreased the odds of uptake.

For the binary responses, the largest increase in odds of uptake was for those who intended to be treated for lung cancer if diagnosed through screening (aOR:1.65;1.45-1.87). Those who perceived smoking cessation as an effective means of reducing lung cancer risk or



thought the chances of surviving early-stage lung cancer were good or fair, also had statistically significantly increased odds of uptake ( $p < .01$ ). Similarly, those who perceived lung cancer as stigmatised were more likely to respond (aOR:1.26;1.14,1.40).

### ***Distribution of the psychological constructs***

Overall, mean scores for each sub-scale were within the middle range (7.03 to 11.27) of possible scores (3-15), although the consequences of lung cancer were perceived more negatively (M:4.65, SD:1.61) while perceptions of early diagnosis were relatively more positive (M:12.63, SD:2.01; Supplementary Table 2). The majority of respondents perceived the chances of surviving lung cancer as good or fair (65.7%; Supplementary Table 3), thought smoking cessation was moderately or extremely effective in reducing lung cancer risk (67.5%), and intended to have surgery for an early-stage lung cancer if detected through screening (79.3%). Half (50.1%) perceived lung cancer to be stigmatised by other people.

Tables 2 and 3 show the adjusted associations between sociodemographic and smoking characteristics, and each psychological construct. Some of the largest associations seen were between gender and emotional representations (with men relatively more positive), Asian ethnicity and lower personal control, and smoking status and risk perceptions (with current smokers reporting the highest risk perceptions).

### **- Tables 2 and 3 -**

Compared with women, men also reported more positive perceptions of personal and treatment control, and a lower perceived risk of lung cancer ( $p < .001$ ). Men were also less likely than women to perceive lung cancer as stigmatised and were more optimistic about survival ( $p < .001$ ). However, scores for coherence suggested lower perceived knowledge about lung cancer among men. There were no statistically significant associations with the other constructs.

Increasing age was associated with more positive perceived consequences, greater treatment control, lower perceived stigma and a higher perceived prospect of surviving early-stage lung cancer. However, older adults felt they had less personal control over lung cancer, held lower perceptions of personal risk, and saw less benefit in smoking cessation and early diagnosis ( $p < .01$ ). Age was not statistically significantly associated with the other constructs.

Relationship status was only associated with treatment control, treatment intentions, perceived chances of survival, and early diagnosis as a behavioural response. In each case, those who were single, separated, widowed, or divorced reported more negative perceptions than those who were married, in a civil partnership or cohabiting ( $p < .01$ ).

Ethnicity was statistically significantly associated with eight of the constructs ( $p < .001$ ). Compared with those of a white ethnic background, participants of black and Asian ethnic backgrounds perceived the consequences of lung cancer and the effectiveness of treatment in controlling lung cancer more positively and were less likely to perceive lung cancer to be stigmatised. However, their coherence (knowledge) of lung cancer was lower. Those of a mixed or other ethnic background also held more positive perceptions of treatment control than participants who were white, with participants of other ethnic minority backgrounds holding more negative perceptions of their personal control over lung cancer, the consequences, their coherence, and the benefits of early diagnosis. Participants of Asian

ethnic backgrounds also held more negative perceptions of early diagnosis, as well as the chances of survival and their emotional response to lung cancer.

Area-level deprivation was statistically significantly associated with five of the constructs ( $p < .01$ ); specifically, greater affluence was associated with greater perceived personal control and benefit from early diagnosis, but more negative perceptions of the consequences of lung cancer. Participants living in more affluent areas were also more likely to perceive lung cancer to be stigmatised and perceive smoking cessation to be less effective in reducing risk.

Smoking status was statistically significantly associated with nine of the constructs ( $p < .01$ ). Current daily smokers tended to report more negative perceptions than former smokers. This included lower personal control over, and higher perceived risk of, lung cancer, as well as lower perceived effectiveness of smoking cessation and higher perceived stigmatisation. Current daily smokers were less willing to be treated for early-stage disease and more pessimistic about survival. Those who smoked occasionally, smoked other types of tobacco, or reported never having smoked at all (despite historical primary care records, see Methods) reported higher perceived risk of lung cancer than former smokers. Participants who smoked other types of tobacco also perceived smoking cessation to be less effective than former smokers.

## DISCUSSION

This is the first study to prospectively investigate psychological correlates of LDCT lung cancer screening uptake behaviour using a large, diverse cohort of high-risk adults. Nearly all the psychological constructs were associated with uptake (defined as phoning to book an LHC at which LDCT screening is offered), including perceptions of controllability, survival, mortality risk-reducing behaviours, treatment, and stigmatisation; although not always in the direction expected. These findings pinpoint specific psychological targets for interventions.

Perceptions of personal control over risk of lung cancer mortality and perceived efficacy of risk-reducing behaviours (i.e., early diagnosis, smoking cessation, and surgical treatment) were positively associated with uptake, as was perceived survival from lung cancer. Most of these constructs were also perceived more negatively by current than former smokers; consistent with previous cross-sectional and qualitative research<sup>14–19</sup>. These psychological constructs therefore provide potentially modifiable targets for interventions designed to improve uptake for a high-risk group less likely to attend lung cancer screening. To date, individual-level psychological interventions for cancer screening uptake have had modest success, likely due to the difficulty of changing deep-rooted perceptions with one-off, individual-level communications. The present study suggests prior interventions were ineffective at modifying these psychological targets rather than psychological factors not being important for uptake. Our findings move evidence forward by pinpointing specific psychological targets for intervention design<sup>14–19</sup>. In line with an experimental medicine approach to health behaviour change<sup>20</sup>, the next step is to test possible methods, modes and mechanisms for changing these targets; evidence which will inform complex intervention design.

Higher perceived risk of lung cancer was also positively associated with uptake, but with current smokers reporting the highest risk perception scores, at odds with their lower participation in lung screening trials<sup>9-11</sup>. This contradiction may be explained by current smokers also holding more of the negative perceptions associated with lower uptake, which could undermine how they behave in response to their high perceived risk. These included more negative perceptions of lung cancer controllability, early diagnosis and survival, lower willingness to be treated, and believing smoking cessation to be less effective in reducing risk. Indeed, according to the SRM<sup>13</sup>, negative perceptions of lung cancer and the efficacy of risk-reducing behaviour, could lower current smokers' motivation to see screening as a way to reduce their risk of lung cancer mortality. Therefore, while perceived risk may be a necessary motivating factor in the main, targeting risk perceptions may be unnecessary for current smokers specifically. Indeed, in the NLST, it appeared to be former smokers who underestimated their risk of lung cancer yet were more likely to attend<sup>27,28</sup>. Furthermore, some studies show the opposite direction of effect, with higher affective risk perceptions retrospectively reported by current smokers declining participation in the UKLS, although there was no comparable attending group<sup>16</sup>. Indeed, systematic reviews of interventions solely targeting risk perceptions show no effect on screening uptake, even when risk information is personalised<sup>29</sup>. The crucial psychological targets for intervention may therefore be those perceptions which optimise behavioural responses to perceived risk rather than risk perceptions themselves.

Associations between the SRQ-LCS constructs and uptake were not always in the direction expected. Perceiving lung cancer to be stigmatised increased the likelihood of uptake; at odds with previous qualitative research<sup>15,18</sup>. Perhaps those most concerned about stigmatisation were less likely to participate and are underrepresented. It might also reflect the present study's measurement of other people's perceptions of stigmatisation<sup>22</sup> rather than personal perceptions. More negative emotional representations of lung cancer similarly increased uptake which was also unexpected. However, it is important to note that the SRM constructs are proposed to be bi-directional<sup>13</sup>. Therefore, if screening is either avoided or attended as a form of emotion-focussed coping, this may feed back into the emotional representation of lung cancer, making it more positive. Future research should investigate how these perceptions might change and interact with uptake behaviour over time and whether combinations of psychological factors better explain uptake.

The measures studied here focussed exclusively on motivational factors and not those affecting capability or opportunity, which may also prevent individuals from realising their intention. Another limitation is the low response rate and possible self-selection bias, although the large sample size and diverse sociodemographic representation strengthen its generalisability. While we oversampled in anticipation of a lower response from those not wishing to be screened, screening uptake was relatively high among questionnaire respondents, indicating bias in response. There is also a possibility that the questionnaire influenced perceptions of lung cancer or prompted uptake by asking about intentions, known as the 'question-behaviour' effect<sup>30</sup>. Last, some participants responded to their LHC invitation before receiving the questionnaire, and so we cannot infer causality. We hope to better understand screening uptake behaviour over time using repeated measures follow-up data from this cohort.

In conclusion, interventions aiming to improve high-risk groups' uptake of LDCT lung cancer screening should target perceptions of lung cancer controllability, survival, and perceived effectiveness of behaviours aimed at reducing the risk of lung cancer mortality, which may

be more effective than trying to change risk perceptions. Experimental studies investigating the methods and mechanisms through which these perceptions could be changed can now inform a complex interventional trial testing these findings. The intervention delivery may demand a multi-level systems strategy, moving beyond one-off, individual-level communications, to more intensive, repeated, and wide-reaching communications.

## ACKNOWLEDGEMENTS

We would like to thank all of the participants who gave up their time to help with this research study. We are also incredibly grateful to all of those who are so dedicated to delivering the SUMMIT Study within which the present study is embedded and therefore supported, which includes all staff at the participating primary care and secondary care sites. More specifically, they thank the Clinical Research Fellows (Carolyn Horst, Sophie Tisi, Helen Hall, Priyam Verghese, Andrew Creamer and Tom Callender), the Cancer Research UK and UCL Clinical Trials Centre (Laura Farrelly, Anne-Marie Mullin, Jonathan Teague, Rachael Sarpong, Malvika Suresh), the Cancer Clinical Trials Unit (Kylie Gyertson, Vicky Bowyer), the Research Nurses and Clinical Trial Practitioners (Alice Cotton, Simranjit Mehta, Kaylene Phua, Colombus Ife, April Neville, Paul Robinson, Laura Green, Zahra Hanif, Helen Kiconco, Ricardo McEwen, Nick Beach) the Data Managers (Sophie Nnorom, Hina Pervez), UCLH operation managers (Fanta Bojang, Claire Levermore, Jeannie Eng, Catherine Nestor), the Lung Health Check contact centre team (Julian McKee, Mark Clark) and the lead Radiologists (Arjun Nair, Anand Devaraj). They would also like to thank all those at GRAIL Inc who have supported the SUMMIT Study, and particularly those who worked on programming the questionnaire mailings for this specific embedded study (Thomas Rooney, Henry Armburg-Jennings, Eduardo Sosa, Jack Galilee, Marcus Foster).

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2018;394-424.
2. Lewer D, Jayatunga W, Aldridge RW, et al. Premature mortality attributable to socioeconomic inequality in England between 2003 and 2018 : an observational study. *Lancet Public Heal.* 2019;2667:1-9.
3. Public Health England. National Disease Registration Service: Staging data in England. [https://www.cancerdata.nhs.uk/stage\\_at\\_diagnosis](https://www.cancerdata.nhs.uk/stage_at_diagnosis); 2018. Accessed 13<sup>th</sup> May 2021.
4. Office for National Statistics (ONS). Cancer survival in England - adults diagnosed. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed>; 2019. Accessed 13<sup>th</sup> May 2021
5. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality

- with Volume CT Screening in a Randomized Trial. *N Engl J Med* 2020; 6: 503-513.
6. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011;365:395-409.
  7. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. *N Engl J Med*. 2013;369:245-254.
  8. Office for National Statistics. Chapter 1 - Smoking ( General Lifestyle Survey Overview - a report on the 2011 General Lifestyle Survey ). [http://www.ons.gov.uk/ons/dcp171776\\_302558.pdf](http://www.ons.gov.uk/ons/dcp171776_302558.pdf); 2013. Accessed 13<sup>th</sup> May 2021.
  9. McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. *Cancer Prev Res* 2014; 7: 362–371.
  10. Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H. Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study. *J Thorac Oncol*. 2015;10:747-753.
  11. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Baseline characteristics of participants in the randomized national lung screening trial. *J Natl Cancer Inst*. 2010;102:1771-1779.
  12. Pham D, Bhandari S, Pinkston C, Oechsli M. Lung Cancer Screening Registry Reveals Low-dose CT Screening Remains Heavily Underutilized. *Clin Lung Cancer*. 2020;21:e206-e211.
  13. Leventhal H, Brissette I, Leventhal EA. The common-sense model of self-regulation of health and illness. In: Cameron LD, Leventhal H, eds. *The Self-Regulation of Health and Illness Behaviour*. London: Routledge; 2003:42-65.
  14. Smits SE, McCutchan GM, Hanson JA, Brain KE. Attitudes towards lung cancer screening in a population sample. *Heal Expect* 2018; 21: 1150–1158.
  15. Quaife SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening within socioeconomically deprived and heavy smoking communities: informing screening communication. *Heal Expect*. 2016;384:1-11.
  16. Ali N, Lifford KJ, Carter B, et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. *BMJ Open* 2015; 5: e008254.
  17. Patel D, Akporobaro A, Chinyanganya N, et al. Attitudes to participation in a lung cancer screening trial: a qualitative study. *Thorax*. 2012;67:418-425.
  18. Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM. A qualitative study exploring why individuals opt out of lung cancer screening. *Fam Pract*. 2017;34:238-244.
  19. Quaife SL, Vrinten C, Ruparel M, et al. Smokers' interest in a lung cancer screening

- programme: a national survey in England. *BMC Cancer*. 2018;18:497.
20. Sheeran P, Klein WMP, Rothman AJ. Health Behavior Change: Moving From Observation to Intervention. *Ann Rev Psych* 2016; 68: 573-600.
  21. Dickson J, Quaife S, Horst C, et al. The SUMMIT Study: invitation strategy and screening uptake of the first 36,680 invited. *Lung Cancer* 2020; 139: S5.
  22. Quaife SL, Brain KE, Stevens C, Kurtidu C, Janes SM, Waller J. Development and psychometric testing of the self-regulatory questionnaire for lung cancer screening (SRQ-LCS). *Psychol Health* 2021; epub ahead of print: DOI:10.1080/08870446.2021.1879806. Accessed 23<sup>rd</sup> June 2021.
  23. Kuipers MAG, Partos T, McNeill A, et al. Smokers' strategies across social grades to minimise the cost of smoking in a period with annual tax increases: Evidence from a national survey in England. *BMJ Open* 2019; 9: 1–9.
  24. Demidenko E. Sample size determination for logistic regression revisited. *Stat Med*. 2007;26:3385-3397.
  25. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: The English Longitudinal Study of Ageing. *Int J Epidemiol* 2013; 42: 1640–1648.
  26. Thompson ME, Fong GT, Hammond D, et al. Methods of the International Tobacco Control (ITC) Four Country Survey. *Tob Control* 2006; 15 Suppl 3: iii12-iii18.
  27. Park ER, Ostroff JS, Rakowski W, et al. Risk perceptions among participants undergoing lung cancer screening: baseline results from the National Lung Screening Trial. *Ann Behav Med* 2009; 37: 268–279.
  28. Park ER, Streck JM, Gareen IF, et al. A qualitative study of lung cancer risk perceptions and smoking beliefs among national lung screening trial participants. *Nicotine Tob Res* 2014; 16: 166–173.
  29. Usher-Smith JA, Silarova B, Sharp SJ, Mills K, Griffin SJ. Effect of interventions incorporating personalised cancer risk information on intentions and behaviour: A systematic review and meta-analysis of randomised controlled trials. *BMJ Open* 2018; 8: 1–13.
  30. Wilding S, Conner M, Sandberg T, et al. The question-behaviour effect: A theoretical and methodological review and meta-analysis. *Eur Rev Soc Psychol* 2016; 27: 196–230.

## TABLE AND FIGURE LEGENDS

**Figure 1** Flow diagram to show inclusion of participants

**Figure 2** Frequency of each screening uptake behaviour by behavioural intentions of those eligible at each stage

**Figure 3** Forest plot of the adjusted associations between each SRQ-LCS psychological construct and screening uptake

**Table 1** Characteristics of the sample

**Table 2** Adjusted regression coefficients for the associations between demographic factors, smoking status, and sub-scale SRQ-LCS scores

**Table 3** Adjusted odds ratios for the associations between demographic factors, smoking status, and single item SRQ-LCS constructs